What is Applied Spectral Imaging?
Applied Spectral Imaging (ASI) specializes in developing and deploying sophisticated computer-aided technologies for digital pathology and cytogenetics. Their comprehensive suite of solutions caters to advanced karyotyping, FISH imaging, and analysis, offering scanner-agnostic capabilities for H&E and IHC staining, alongside tools for tissue matching with FISH specimens. Serving pathology and cytogenetic laboratories worldwide, ASI leverages over three decades of experience to foster personalized customer relationships and deliver innovative diagnostic solutions. The company's commitment to personalized customer relationships and cutting-edge diagnostic tools positions it as a key player in the evolving landscape of personalized medicine and advanced diagnostics.
How much funding has Applied Spectral Imaging raised?
Applied Spectral Imaging has raised a total of $409K across 2 funding rounds:
Debt
$150K
Debt
$259K
Debt (2020): $150K with participation from PPP
Debt (2021): $259K led by PPP
What's next for Applied Spectral Imaging?
With the recent infusion of $259K in a major strategic investment, Applied Spectral Imaging is poised for accelerated expansion and further innovation in the digital pathology and cytogenetics markets. This large-scale late-stage funding suggests a focus on scaling operations, enhancing its technological portfolio, and potentially broadening its global reach. ASI's strategic capital allocation will likely support advancements in AI-driven diagnostic tools and the integration of its solutions into more clinical workflows, reinforcing its role in advancing diagnostic accuracy and efficiency within the biomedical imaging field.
See full Applied Spectral Imaging company page
